Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today announced the presentation to the Centers for Medicare and Medicaid Services of its case study highlighting the potential clinical benefit and cost savings of its SurgWerks A -CLI cell therapy for treatment of non-operable Critical Limb Ischemia .
http://ift.tt/1sBZfcV
http://ift.tt/1sBZfcV
No comments:
Post a Comment